SEC Comment Letter 0000000000-25-000651 to Monopar Therapeutics (MNPR)
Monopar Therapeutics
Date: Jan. 22, 2025 · CIK: 0001645469 · Accession: 0000000000-25-000651
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284304
Letter
January 22, 2025 Chandler Robinson Chief Executive Officer Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, IL 60091 Re:Monopar Therapeutics Inc. Registration Statement on Form S-3 Filed January 15, 2025 File No. 333-284304 Dear Chandler Robinson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:John J. Harrington, Esq.
Show Raw Text
January 22, 2025
Chandler Robinson
Chief Executive Officer
Monopar Therapeutics Inc.
1000 Skokie Blvd., Suite 350
Wilmette, IL 60091
Re:Monopar Therapeutics Inc.
Registration Statement on Form S-3
Filed January 15, 2025
File No. 333-284304
Dear Chandler Robinson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:John J. Harrington, Esq.